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Abstract. p53 is an oncosuppressor protein, which acts via 
transcriptional and non-transcriptional mechanisms. The 
transcriptional function of p53 is mediated by specific 
responsive elements. In the present study we found active 
responsive elements, specific for the p53 within the 5'flanking 
region and within the first intron of the gene encoding for the 
CD59 membrane inhibitor of reactive lysis, and within the first 
intron of the gene encoding for the CD58 membrane protein 
(LFA-3). The results suggest that p53 may enhance the 
transcription of both CD59 and CD58 and imply a novel role 
for p53 as a direct regulator of the immune response. 
p53 is a tumor suppressor protein involved in vital aspects 
of cell life, such as control of the cell cycle checkpoints Gl 
and G2, maintenance of genomic integrity, DNA repair, 
replication, transcription, programmed cell death 
(apoptosis) and differentiation. The majority of stimuli 
causing p53 activation such as hypoxia/oxidative stress (1, 
2), or UV radiation (3) are accompanied by inflammatory 
reactions. Additionally, a variety of cytokines secreted as a 
result of inflammation, such as IL · ! and TNFa, induce p53 
(4,5). 
p53 protein is assumed to exert its effect through its 
ability to function as a sequence-specific DNA-binding 
transcription factor. Wild-type p53 binds to double-
stranded DNA homologous or identical to consensus 
sequence containing two decamers of the type: Pu Pu Pu C 
A/T T/A G Py Py Py, separated by 0 to 13 bp (6). The list of 
genes that possess these DNA sites is rapidly increasing and 
includes: p21/WAFl, MDM2, GADD45, ΒΑΧ, cyclin G, 
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cyclin D, IGF-BP3, PCDNA, TGF-a, Ras and p53 itself (7-
17). The genes noted above contain p53-binding sites either 
in their promoter regions or within their introns. Recently 
p53 has been reported to enhance the transcription of a 
GPI-linked membrane protein GML (18) which is related 
to apoptosis and participates in the sensitization of 
malignant cells to chemotherapy and inflammation (19, 20). 
GML exhibits a great homology with the membrane 
inhibitor of the reactive lysis CD59 (21). CD59 is a 18-25 
kDa GPI-linked protein with a broad tissue distribution 
that prevents the formation of the complement membrane 
attack complex (MAC) on the surface of homologous cells 
(22). Furthermore, CD59, along with the lymphocyte 
function-associated antigen-3 (LFA-3, CD58), participates 
in the activation of Τ lymphocytes and NK cells by binding 
to CD2. Recently, CD59 and CD58 have been identified as 
genes which possess potential p53-responsive elements (28). 
Given that inflammation is related to high levels of p53 (4, 
5), as well as to high levels of CD59 (23-25) and CD58 (26, 
27), a possible participation of p53 in the immune response 
by affecting the levels of CD59 and CD58, has been 
hypothesized (28). 
In the present study, we have examined the possibility of 
the consensus sequences of p53 in the promoter area of the 
CD59 gene and in the intron 1 of the CD59 and CD58 
genes regulating promoter activity in a p53-dependent 
manner. 
Materials and Methods 
Cell culture. Saos2 osteosarcoma cells, were cultured in Dulbecco's 
modified Eagle medium (DMEM) containing 4 mM L-glutamine, 50 
μg/ml penicillin and 50 μg/ml streptomycin supplemented with 10% 
fetal calf serum. The cells were incubated at 37gC in a humidified 
atmosphere of 5% CO2. 
Plasmids. The 39 bp fragment (5' TAAGGAGACATGCTTTAA-
ATATCAAAGCAAG-TCATCCTG 3') which contains the potential 
p53-responsive element CD59a, the 42 bp fragment (5'TACTTAGGC-
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Figure 1. Electrophoretic mobility shift assay showing sequence-specific binding of the p53 to the putative p53 responsive elements of the CD59 and CD58 
genes. Lane 2: in vitro translated wild-type p53 protein, in the presence of nuclear extracts from Saos2 cells, binds with the CD59a end-labeled 
oligonucleotide and forms a retarded band (lower arrow). Lane 2: in vitro translated wild-type p53 protein,in the presence of nuclear extracts from Saos2 
cells, binds with the CD59a end-labeled oligonucleotide in the presence of the monoclonal antibody PAb421 and forms a super-shifted retard band 
indicating the specific binding of the p53 protein (upper arrow). Addition of mutant oligonucleotide to the reaction did not compete with the formation of the 
specific complex. Lanes 3, 4: in vitro translated wild-type p53 protein ,in the presence of nuclear extracts from Saos2 cells, binds respectively with the CD58 
and WAFl end-labeled oligonucleotides and form a retarded band (lower arrow). Lanes 5, 6: in vitro translated wild-type p53 protein, in the presence of 
nuclear extracts from Saos2celb, binds with CD58and WAFl end-labeled oligonucleotides in the presence of the monoclonal antibody PAM21 and forms a 
super-shifted retard band indicating the specific binding of the p53 protein. Addition of mutant oligonucleotide to the reaction did not compete with the 
formation of the specific complex (upper arrow). 
AAGTTCAAAACCTCCCTAAGCTTTGGCTTCTTT 3') that con­
tains the potential p53-responsive element CD59b, the 39 bp fragment 
(5'TTAAAGAGTAAGCTCCAC-ATGGTCAAACATGTTCTTACT 
3') which contains the potential p53-responsive element CD58 and the 
20 bp fragment (5' GAACATGTCCCAACATGTTC 3') containing 
the p53-responsive element of the WAFl gene (29), were synthesized 
and cloned upstream of a minimal HSV promoter and a firefly human 
secreted placental alkaline phosphatase (SEAP) reporter gene of the 
mammalian expression vector pTKSeap (30). The resulting constructs 
were designated pTKSeapCD59a, pTKSeapCD59b, pTKSeapCD58 
and pEp21TKSeap, respectively. 
EMSA. The electrophoretic mobility shift assay (EMSA) probes were 
the 39 bp (CD59a), the 42 bp (CD59b), the 39 bp (CD58) and the 20 
bp (WAFl) oligonucleotides containing a potential p53-responsive 
element in the CD59, CD58 and WAFl genes, respectively. End-
labelling was performed using T4 polynucleotide kinase (Boehringer, 
Mannheim, Germany) and [a P]ATP according to standard protocol 
(31). The end-labeling oligonucleotides were mixed in 0.1M sodium 
chloride, heated at 95eC for 5 minutes and then gradually cooled to 
room temperature to allow annealing. Ten μg of nuclear extracts were 
pre-incubated for 10 minutes with 100 ng of purified monoclonal 
antibody PAb421 to activate specific DNA binding of the p53 protein. 
It has been shown that p53 binds non-specifically to DNA through the 
carboxy-terminal domain, locking p53 in a conformation that cannot 
bind its specific element. By adding PAb421, non-specific binding is 
inhibited and p53 adopts the specific DNA conformation (32). 
Furthermore, nuclear extracts from p53-null cells (Saos2) were added 
to the reaction, in order to get in vitro translated p53 to bind the p53-
responsive element (33). Subsequently, 1 ng of labelled 
oligonucleotide in the presence of 500 ng of poly (di)-poly (dC) as non­
specific DNA competitor was added. All incubations took place on ice 
with the following binding conditions: 50 mM potassium chloride, 25 
mM Hepes pH 7.6, 5 mM DTT, 10 μg of leupeptin per ml, 0.05% 
Triton X-100 and 20% glycerol. Competitior experiments were 
performed by preincubated PAb421-activated extracts with 50-fold 
molar excess of unlabeled oligonucleotides or using mutant labeled 
oligonucleotide. In vitro translated p53 protein was used as a positive 
control in the DNA binding experiments (34). Protein-DNa binding 
reactions were analysed on a 4% Polyacrylamide gel. The gels were 
dried and exposed on radiograph film (RX Fuji) at -70 "C. 
Transient transfections and Seap assay. For each transfection 
1 μg of the corresponding reporter plasmid (pTKSeap-
CD59a, pTKSeapCD59b, pTKSeapCD58, pEp21TKSeap 
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Table I. Comparison ofp53 consensus sequences. 
Gene of origin / promoter position p53 consensus site 
consensus PuPuPuC(A/T) (T/A) GPyPyPy 
WAF1/-2235/-2215 GAACATGTCC CAACATGTTG 
CD59a/-1675/-1626 AGACATGCTTTAAATATCAAAGCAAGTCA 
CD59b/-68W-6«) AGGCAAGTTCAAAACCTCCCrAAGCnTGG 
CD58/-156/-108 GAGTAAGCTCCACATGGTCAAACATGTTC 
Underline indicates deviations from consensus. Bold letters indicate 
center bases of consensus sequence. 
«£. 80 
WAF1RE OD69aRE CD59bRE C058RE pTKSeap 
and empty pTKSeap) was mixed with 1 μg of the expression 
vector encoding wt p53 (pSV2hp53BSwt), and with 1 ng 
pSV promoter-ß-galactosidase (Stratagene, San Luis 
Ohipso, CA, USA) in DMEM medium. Ten μΐ of diluted in 
DMEM (1:100) Transfectam reagent (Promega, La Jolla, 
CA, USA) was immediately added to the plasmid mixture. 
The Tranfectam/plasmid mixture was then added directly to 
5 χ 10 exponentially growing Saos2 cells in DMEM 
medium (without serum). The cells were incubated at 37°C 
with 5% CO2 for 48 hours. The transcriptional activity was 
examined 48 hours post-transfection by measuring the 
levels of SEAP activity using the Great EscAPe SEAP 
Genetic Reporter System (Clontech, Palo Alto, CA, USA) 
according to the manufacturer's instructions. Successful 
transfection was verified by measuring the ß-galactosidase 
activity. 
Results and Discussion 
Many of the biological functions of p53 are believed to be 
regulated by downstream genes so that understanding of 
the function of p53 will require examination of these 
downstream genes. The CD59 and CD58 genes have been 
identified as candidate targets of p53 (28). Via computer 
search, using the BLAST program (NHI), we revealed the 
presence of: a) a perfect half-binding site followed by one 
imperfect half- binding site with the interference of 9 
nucleotides for p53, located in the 5'flanking region 
(ranging from nucleotide -1665 to -1637 upstream of exon 
1) but not within the promoter limits of the CD59 gene 
(CD59a responsive element); b) a perfect half-binding site 
followed by two imperfect half-binding sites for p53 located 
in intron 1 of the CD59 gene (ranging from nucleotide -675 
to -645 upstream of exon 2) but not within the enhancer 
limits (CD59b responsive element) and; c) a perfect half-
binding site followed by one imperfect half-binding site for 
Figure 2. Effects of the pS3 responsive elements on the transcriptional 
activity of the SEAP reporter gene of the pTKSeap plasmid in the presence 
of wild-type p53. The total amount of DNA transfected in each experiment 
was 2 μg (1 μ% of wild-type p53 and 1 μ% of the reporter plasmid). Activity 
was expressed as a percentage of that induced by 1 μg of the reporter gene 
downstream of the WAFl responsive element in the presence of wild-type 
p53. The results shown are an average of three independent transfection 
experiments. 
p53 with the interference of 9 nucleotides, located in the 
first intron of the CD58 gene (ranging from nucleotide -146 
to -118 upstream of exon 2) (CD58 responsive element). 
The imperfect half-binding site of the CD59a-responsive 
element displays a 95% homology with the Pu Pu Pu C Α/Τ 
T/A G Py Py Py motif whereas, the first imperfect half-
binding site of CD59b displays an 80% homology with the 
motif and the second half-binding site a 70% homology. 
The CD58-responsive element displays a 95% homology 
with the motif (Table I, 28). 
To determine whether the p53 protein could bind 
specifically to the CD59a, CD59b and CD58 putative-
responsive elements, EMSAs were performed. The results 
presented in Figure 1 reveal a specific retard band, which 
was abolished in the presence of a mutated-responsive 
element as well as in the presence of excess unlabelled p53-
responsive element. 
To explore the functional significance of this new 
potential p53-binding site, SEAP reporter gene plasmids 
containing the CD59a, CD59b and CD58-responsive 
sequences were constructed. Contransfection assays were 
then performed into Saos2 cells (which are deficient in p53) 
using the above constructs, or the empty vector, and a 
plasmid coding for wild-type p53 (pSV2hp53BSwt). The 
results were compared with those obtained with the 
reporter plasmid pEp21TKSeap containing the p53-
responsive element of WAFl gene. Contransfection of 
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pTKSeapCD59a with the plasmid encoding the wild-type 
p53 resulted in the 100% activation of the SEAP activity as 
compared to results obtained with the WAF1 p53-
responsive element (Figure 2). Under the same conditions 
the CD59b and the CD58 resulted in 98% and 60% 
activation of the SEAP activity, respectively (Figure 2). No 
stimulation was observed when cells were transfected with 
the pTKSeap vector in the presence of the pSV2hp53BSwt 
plasmid. On the basis of these results, the sequences 
identified by computer could confer p53 responsiveness to 
the CD59 and CD58 gene promoters. 
Taking into consideration that inflammation is related to 
high levels of p53 (4, 5, 35) and that in an inflammatory 
environment the elevated levels of activated-complement 
render cells susceptible to complement-mediated lysis, it is 
possible that the CD59 up-regulation by activated-p53 may 
contribute to the protection of host cells from complement 
attack. The CD58 up-regulation by activated-p53 may also 
function as part of a regulatory pathway for the 
enhancement of the inflammatory process. Additionally, the 
p53-mediated CD58 up-regulation might contribute to the 
immune surveillance against cancer since the up-regulated 
wild-type p53 and a consequently CD58 might lead to the 
recognition of cancerous cells by NK cells via the CD58-
CD2 interaction (36-38). The mutant p53 may disrupt this 
mechanism and thus constitute a way of tumour immune 
evasion. 
Our data collectively manifest two new potential "target" 
genes, CD59 and CD58, for p53 and raise a new role for 
p53, in immune regulation. 
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